Chief Accounting Officer and Vice President, Finance
Silk Road Medical Inc
Effective
2023-03-09
Filed
March 15, 2023, 7:59 PM ET
On March 9, 2023, the Board of Directors of Silk Road Medical, Inc. (the “Company”) appointed Mhairi Jones, age 52, as Chief Accounting Officer and Vice President, Finance, effective immediately.
Role change
Lucas W. Buchanan
Chief Financial Officer and Chief Operating Officer
Silk Road Medical Inc
Effective
2023-03-09
Successor
Mhairi Jones
Filed
March 15, 2023, 7:59 PM ET
As a result of Ms. Jones’s appointment, Lucas W. Buchanan, the Company’s Chief Financial Officer and Chief Operating Officer, will no longer serve as the Company’s principal accounting officer but will remain as the Company’s principal financial officer.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Mhairi Jones was appointed as Chief Accounting Officer and Vice President, Finance at Silk Road Medical Inc.
Action
appointed
Role
Chief Accounting Officer and Vice President, Finance
Exact text from the filing
On March 9, 2023, the Board of Directors of Silk Road Medical, Inc. (the “Company”) appointed Mhairi Jones, age 52, as Chief Accounting Officer and Vice President, Finance, effective immediately.
Lucas W. Buchanan changed role as Chief Financial Officer and Chief Operating Officer at Silk Road Medical Inc.
Action
will no longer serve as principal accounting officer
Role
Chief Financial Officer and Chief Operating Officer
Exact text from the filing
As a result of Ms. Jones’s appointment, Lucas W. Buchanan, the Company’s Chief Financial Officer and Chief Operating Officer, will no longer serve as the Company’s principal accounting officer but will remain as the Company’s principal financial officer.
Silk Road Medical Inc: Amended and Restated Bylaws incorporating changes for universal proxy rules, DGCL amendments, and procedural updates (effective 2023-03-15).
Change
bylaw amendment
Effective
2023-03-15
Exact text from the filing
Also on March 9, 2023, the Company’s Board of Directors (the “Board”) approved and adopted Amended and Restated Bylaws (the “Amended and Restated Bylaws”) incorporating certain amendments, including amendments in response to the new universal proxy rules promulgated by the Securities and Exchange Commission (the “SEC”) and recent amendments to the Delaware General Corporation Law (the “DGCL”). The Amended and Restated Bylaws will become effective as of March 15, 2023.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.